Form 4 for TMO Thermo Fisher Scientific
Accepted 2026-02-27 00:00:00 ET · period of report 2026-02-25 · accession 0000097745-26-000037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-27 | 2026-02-25 | TMO | Williamson Stephen | SVP, CFO | A - Grant | $0.00 | +1,534 | 33.4K | +5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-25 | A | A | 1,534 | $0.00 | 33,421.19 | D | — | — | (F1) Shares represent a performance-based restricted stock unit award granted on February 19, 2025. On February 25, 2026, the Compensation Committee certified achievement of the applicable performance criteria. The award vests in three equal tranches on February 28, 2026, 2027 and 2028, in accordance with the terms of the award agreement. |